drugset / Trial / NCT00294671
The Effect of Diflunisal on Familial Amyloidosis
Phase 2/3
Completed
130 enrolled
Boston University
Food and Drug Administration (FDA) · collabNational Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine if diflunisal can prevent progressive lower leg nerve damage in patients with familial amyloidosis polyneuropathy. Funding Source - FDA Office of Orphan Products Development (OOPD); National Institute of Neurological Disorders and Stroke (NINDS)
Timeline
- Start
- 2006-02
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | diflunisal | Small molecule | 250 mg | Oral |